

# Revised HOME-CoV - Study on the implementation of the revised HOME-CoV score to guide the choice of hospitalisation or outpatient management of patients with confirmed or probable SARS-CoV-2 infection admitted to an emergency department.

Head :Douillet Delphine

Last update : 05/05/2021 | Version : 1 | ID : 73909

## General

### Identification

Detailed name Study on the implementation of the revised HOME-CoV score to guide the choice of hospitalisation or outpatient management of patients with confirmed or probable SARS-CoV-2 infection admitted to an emergency department.

Sign or acronym Revised HOME-CoV

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation 2020-A03067-32

### General Aspects

Medical area Emergency medicine

Study in connection with Covid-19 Yes

Health determinants Healthcare system and access to health care services

### Scientific investigator(s) (Contact)

Name of the director Douillet

Surname Delphine

Address Departement de Médecine d'Urgence<br>4 rue Larrey<br>CHU ANGERS

Email Delphine.Douillet@chu-angers.fr

### Collaborations

## Funding

Funding status Public

Details Angers University Hospital

## Governance of the database

Sponsor(s) or organisation(s) responsible Angers University Hospital

Organisation status

## Additional contact

## Main features

## Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Another treatment or procedure

Database recruitment is carried out as part of an interventional study Yes

Details Performed at group level (clusters)

## Database objective

Main objective

The primary objective is to demonstrate the reliability and safety of outpatient management among patients highly suspected or confirmed as infected with COVID-19, attending an emergency department and with a revised HOME-CoV score less than 2 (negative rule).

The secondary objectives are as follows:

- i. Evaluate the rate of patients having required hospitalisation within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- ii. Evaluate the rate of patients having required hospitalisation and initiation of oxygen therapy within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.

- iii. Evaluate the rate of patients having required intubation within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- iv. Evaluate the rate of all-cause deaths within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- v. Evaluate the performance of the revised HOME-CoV score in predicting a negative outcome in the patient subgroup with SARS-CoV-2 infection confirmed by RT-PCR to rule out the risk of a negative outcome when assessed as low risk.
- vi. Compare the performance of the revised HOME-CoV score with that of other existing scores.

Inclusion criteria	<p>Adult patient (&gt; 18 years),</p> <ul style="list-style-type: none"> <li>- Attending one of the emergency departments taking part in the study due to COVID-19 infection confirmed by SARS-CoV-2 positive RT-PCR, or considered highly probable by the physician managing the patient,</li> <li>- Not requiring management in a continuous care or intensive care unit, and subject to a decision to limit active treatment,</li> <li>- Having given their formal consent to take part in the study,</li> <li>- Registered with or a beneficiary of a social security scheme.</li> </ul>
<b>Population type</b>	
Age	<p>Adulthood (19 to 24 years)          Adulthood (25 to 44 years)          Adulthood (45 to 64 years)          Elderly (65 to 79 years)          Great age (80 years and more)</p>
Population covered	Sick population
Pathology	B33 - Other viral diseases, not elsewhere classified
Gender	<p>Male          Woman</p>
Geography area	International
Detail of the geography area	France Belgium
<b>Data collection</b>	
<b>Dates</b>	

## Size of the database

Size of the database (number of individuals) [1000-10 000[ individuals

Details of the number of individuals 1,300 patients

## Data

Database activity Current data collection

Type of data collected  
Clinical data  
Declarative data  
Paraclinical data  
Biological data  
Administrative data

Clinical data (detail) Direct physical measures  
Medical registration

Declarative data (detail) Face to face interview

## Procedures

Followed pathology

## Promotion and access

Promotion

Access